Extracellular vesicle fusion protein and use thereof

By localizing polypeptides and RNA-binding polypeptides that are located in the exovesicles and fusion proteins, combining with the CRISPR/Cas system, the problem of low exosome yield is solved, and the screening of genes affecting the production of exovesicles is achieved, and the exosomes are improved. Yield and purity enhance their potential in clinical applications.

WO2024230738A1PCT designated stage expired Publication Date: 2024-11-14TINGO EXOSOMES TECH CO LTD

Patent Information

Application Number
PCT/CN2024/091738
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2024-05-08
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The storage stability and low yield of exosomes in the prior art limits their clinical application in the field of disease diagnosis and treatment, and a system is needed to screen genes that affect cell production of exosomes to improve exosome yield and purity.

Method used

Provide a fusion protein and screening system, including polypeptides and RNA-binding polypeptides localized to the exovesicles, screen genes that affect exovesicles production through the CRISPR/Cas system, and use barcode sequences and regulatory elements to improve the production and purity of exosomes. .

Benefits of technology

The screening of genes that affect exovesicles production is achieved, the yield and purity of exosomes are improved, and new insights into the mechanisms of cell secretion of exosomes are provided, which enhances its application potential in the field of diagnosis and treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024091738-FTAPPB-I100001
    Figure PCTCN2024091738-FTAPPB-I100001
  • Figure PCTCN2024091738-FTAPPB-I100002
    Figure PCTCN2024091738-FTAPPB-I100002
  • Figure PCTCN2024091738-FTAPPB-I100003
    Figure PCTCN2024091738-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention relates to an extracellular vesicle fusion protein and the use thereof. Specifically, the fusion protein comprises: a polypeptide located in the extracellular vesicle or a functional variant thereof; and an RNA-binding polypeptide or a functional variant thereof. The present invention also relates to a screening system comprising an extracellular vesicle targeting region and a screening region, and a method of screening a gene that affects the generation of extracellular vesicles.
Need to check novelty before this filing date? Find Prior Art

Description

Extracellular vesicle fusion protein and its application Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to an exosome fusion protein, a system comprising the fusion protein, and applications thereof. Background Art

[0002] Almost all mammalian cells secrete exosomes, nanosized extracellular vesicles with a size range of 30 to 200 nm. Exosomes are formed by continuous invagination of the plasma membrane through a variety of metabolic processes, resulting in a diverse composition. Encapsulated in a lipid bilayer, they form spherical structures carrying a variety of biomolecules, including proteins, glycans, lipids, and metabolites. When taken up by other cells, these substances are transferred and influence the phenotype of the recipient cells. Therefore, exosomes are considered important mediators of cell-to-cell communication, transmitting information to neighboring or distant cells, thereby altering their behavior. Furthermore, donor cells can reuptake their own exosomes. Therefore, exosomes play a vital role in both physiological and pathological processes.

[0003] Compared to synthetic carriers such as liposomes and nanoparticles, exosomes offer broad and unique advantages due to their endogenous nature and heterogeneity in disease diagnosis and treatment. However, their clinical application is limited by issues such as storage stability and low yield. Therefore, a system is needed to screen for genes that influence exosome production in cells, thereby enabling increased exosome production and large-scale purification, and providing new insights into the mechanisms of exosome secretion.

[0004] Summary of the Invention

[0005] In order to solve one of the above-mentioned technical problems existing in the prior art, the present disclosure provides a fusion protein and a screening system for screening genes that affect the production of extracellular vesicles by cells, and applications thereof.

[0006] According to one aspect of the present disclosure, a fusion protein is provided, comprising: a polypeptide localized in extracellular vesicles or a functional variant thereof; and an RNA-binding polypeptide or a functional variant thereof.

[0007] In some embodiments, the polypeptide localized in the extracellular vesicle is not particularly limited, and theoretically includes any polypeptide localized on the extracellular vesicle. In some embodiments, the polypeptide localized in the extracellular vesicle includes, but is not limited to, CD9, CD53, CD63, CD81, CD54, CD50, FLOT1, FLOT2, CD49d, CD71 (also known as transferrin receptor), CD133, CD138 (syndecan-1), CD235a, prostaglandin F2 receptor negative regulator (PTGFRN), brain acid soluble protein 1 (BASP1), basigin (BSG) protein, myristoylated alanine-rich protein kinase C substrate (MARCKS), myristoylated alanine-rich protein kinase C substrate-like protein 1 (MARCKSL1), ALIX, syndecan binding protein 1 (Syndecan Binding Protein,SDCBP), Syntenin-2, Lamp2a, Lamp2b, TSPAN8, syndecan-1, syndecan-2, syndecan-3, syndecan-4, TSPAN14, CD37, CD82, CD151, CD231, CD102, NOTCH1, NOTCH2, NOTCH3, NOTCH4, DLL1, DLL4, JAG1, JAG2, integrin alpha-4 (ITGA4), integrin beta-1 (ITGB1), ITGB5, ITGB6, ITGB7, 4F2 cell surface antigen heavy chain (SLC3A2), CD11a, CD11b, CD11c, CD18 / ITGB2, CD41, CD49b, CD49c, CD4 9e, CD51, CD61, CD104, Fc receptors, interleukin receptors, immunoglobulin superfamily members (e.g., IGSF2, IGSF3, IGSF8, etc.), MHC-I or MHC-II components, CD2, CD3ε, CD3ζ, CD13, CD18, CD19, CD30, CD34, CD36, CD40, CD40L, CD44, CD45, CD45RA, CD47, CD86, CD110, CD111, CD115, CD117 , CD125, CD135, CD184, CD200, CD279, CD273, CD274, CD362, COL6A1, AGRN, EGFR, GAPDH, GLUR2, GLUR3, HLA-DM, HSPG2, L1CAM, LAMB1, LAMC1, ARRDC1, LFA-1, LGALS3BP, Mac-1α, Mac-1β, MFGE8, PTGFRN, SLIT2, STX3, TCRA, TCR B, TCRD, TCRG, TSG101, VTI1A, VTI1B, fibronectin, RAB7 (also known as RAB7A), 14-3-3ζ / δ, 14-3-3ε, HSC70, HSP90, HSPA13, ATP transporter (e.g., ATP1A1 protein, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3, ATP2B, etc.), and any combination, functional variant, fragment or domain thereof. In some embodiments, the functional variant of the polypeptide localized in the extracellular vesicle comprises a polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the polypeptide localized in the extracellular vesicle by deletion, insertion or substitution of one or more amino acids in its amino acid sequence.And still able to locate the polypeptide in the extracellular vesicle.

[0008] In some embodiments, the polypeptide localized in the exosome can be a transmembrane or membrane-associated polypeptide. In some embodiments, the polypeptide localized in the exosome can be a polypeptide localized inside the exosome.

[0009] In some embodiments, the polypeptide localized in extracellular vesicles can be selected from IGSF8, CD9, CD63, CD81, PTGFRN, BASP1, BSG, MARCKS, MARCKSL1, ALIX, SDCBP, etc., or any combination, functional variant, fragment or domain thereof. In some embodiments, the polypeptide localized in extracellular vesicles can be BASP1, CD63, SDCBP, or any combination, functional variant, fragment or domain thereof.

[0010] In some embodiments, the polypeptide localized in the extracellular vesicle can have an amino acid sequence as shown in SEQ ID NO: 1, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 1.

[0011] In some embodiments, the polypeptide localized in the extracellular vesicle can have an amino acid sequence as shown in SEQ ID NO: 2, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 2.

[0012] In some embodiments, the polypeptide localized in the extracellular vesicle can have an amino acid sequence as shown in SEQ ID NO: 3, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 3.

[0013] In some embodiments, the polypeptide of the exosome or its functional variant forms a fusion protein with the RNA-binding polypeptide or its functional variant. In some embodiments, the polypeptide of the exosome or its functional variant is linked to the RNA-binding polypeptide or its functional variant directly or via a linker.

[0014] In some embodiments, the RNA-binding polypeptide can be selected from, but is not limited to, Ku protein, Sm7 protein, MS2 coat protein (MCP), PP7 coat protein (PCP), λN protein, Com RNA-binding protein, aptamer, or any combination, functional variant, fragment or domain thereof. In some embodiments, the RNA-binding polypeptide can be MS2 coat protein (MCP), PP7 coat protein (PCP), λN22 protein, or any combination, functional variant, fragment or domain thereof.

[0015] In some embodiments, the RNA-binding polypeptide can have an amino acid sequence as shown in SEQ ID NO:4, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence as shown in SEQ ID NO:4.

[0016] In some embodiments, the RNA-binding polypeptide can have the amino acid sequence as shown in SEQ ID NO:9, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to the amino acid sequence as shown in SEQ ID NO:9.

[0017] In some embodiments, the RNA-binding polypeptide can have an amino acid sequence as shown in SEQ ID NO: 10, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence as shown in SEQ ID NO: 10.

[0018] In some embodiments, the extracellular vesicle-localized polypeptide can be linked to the RNA-binding polypeptide via a linker.

[0019] In some embodiments, the fusion protein of the present disclosure enables the RNA binding polypeptide to be localized inside the exosome. In some embodiments, the RNA binding polypeptide can be localized inside the exosome together with the therapeutic nucleic acid sequence.

[0020] According to another aspect of the present disclosure, a screening system is provided, comprising: an extracellular vesicle targeting region represented by AB (Formula I), wherein A is a polypeptide localized in extracellular vesicles or a functional variant thereof, or a nucleotide sequence encoding thereof, and B is an RNA-binding polypeptide or a functional variant thereof, or a nucleotide sequence encoding thereof; and a screening region represented by CDE (Formula II), wherein C is a nucleotide sequence encoding a first RNA motif, D is a barcode sequence, and E is a nucleotide sequence encoding a second RNA motif, wherein the first RNA motif is complementary to the target sequence, and the second RNA motif is an RNA sequence specifically recognized and bound by B.

[0021] In some embodiments, the extracellular vesicles may include one or more of exosomes, microvesicles, apoptotic bodies, tumor vesicles, nanovesicles, or other extracellular vesicles.

[0022] In some embodiments, the polypeptide localized in the extracellular vesicle is not particularly limited, and theoretically includes any polypeptide localized on the extracellular vesicle. In some embodiments, the polypeptide localized in the extracellular vesicle includes, but is not limited to, CD9, CD53, CD63, CD81, CD54, CD50, FLOT1, FLOT2, CD49d, CD71 (also known as transferrin receptor), CD133, CD138 (syndecan-1), CD235a, prostaglandin F2 receptor negative regulator (PTGFRN), brain acid soluble protein 1 (BASP1), basigin (BSG) protein, myristoylated alanine-rich protein kinase C substrate (MARCKS), myristoylated alanine-rich protein kinase C substrate-like protein 1 (MARCKSL1), ALIX, syndecan binding protein (Syndecan Binding Protein,SDCBP), Syntenin-2, Lamp2a, Lamp2b, TSPAN8, syndecan-1, syndecan-2, syndecan-3, syndecan-4, TSPAN14, CD37, CD82, CD151, CD231, CD102, NOTCH1, NOTCH2, NOTCH3, NOTCH4, DLL1, DLL4, JAG1, JAG2, integrin alpha-4 (ITGA4), integrin beta-1 (ITGB1), ITGB 5. ITGB6, ITGB7, 4F2 cell surface antigen heavy chain (SLC3A2), CD11a, CD11b, CD11c, CD18 / ITGB2, CD41, CD49b, CD49c, CD49e, CD51, CD61, CD104, Fc receptor, interleukin receptor, immunoglobulin superfamily members (such as IGSF2, IGSF3, IGSF8, etc.), MHC-I or MHC-II components, CD2, CD3ε, CD3ζ, CD13, CD18, CD19, CD30, CD34, CD36, CD40, C D40L, CD44, CD45, CD45RA, CD47, CD86, CD110, CD111, CD115, CD117, CD125, CD135, CD184, CD200, CD279, CD273, CD274, CD362, C OL6A1, AGRN, EGFR, GAPDH, GLUR2, GLUR3, HLA-DM, HSPG2, L1CAM, LAMB1, LAMC1, ARRDC1, LFA-1, LGALS3BP, Mac-1α, Mac-1β, MFGE8 , PTGFRN, SLIT2, STX3, TCRA, TCRB, TCRD, TCRG, TSG101, VTI1A, VTI1B, fibronectin, RAB7 (also known as RAB7A), 14-3-3ζ / δ, 14-3-3ε, HSC70, HSP90, HSPA13, ATP transporter (e.g., ATP1A1 protein, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3, ATP2B, etc.), and any combination, functional variant, fragment or domain thereof. In some embodiments, the functional variant of the polypeptide localized in the extracellular vesicles comprises a deletion, insertion or substitution of one or more amino acids in its amino acid sequence, so that its amino acid sequence has at least 70%, at least 75%, at least 80%, at least 85%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the polypeptide localized in the extracellular vesicles.And still able to locate the polypeptide in the extracellular vesicle.

[0023] In some embodiments, the polypeptide localized in the exosome can be a transmembrane or membrane-associated polypeptide. In some embodiments, the polypeptide localized in the exosome can be a polypeptide localized inside the exosome.

[0024] In some embodiments, the polypeptide localized in extracellular vesicles can be selected from IGSF8, CD9, CD63, CD81, PTGFRN, BASP1, BSG, MARCKS, MARCKSL1, ALIX, SDCBP, etc., or any combination, functional variant, fragment or domain thereof. In some embodiments, the polypeptide localized in extracellular vesicles can be BASP1, CD63, SDCBP, or any combination, functional variant, fragment or domain thereof.

[0025] In some embodiments, the polypeptide localized in the extracellular vesicle can have an amino acid sequence as shown in SEQ ID NO: 1, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 1.

[0026] In some embodiments, the polypeptide localized in the extracellular vesicle can have an amino acid sequence as shown in SEQ ID NO: 2, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 2.

[0027] In some embodiments, the polypeptide localized in the extracellular vesicle can have an amino acid sequence as shown in SEQ ID NO: 3, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 3.

[0028] In some embodiments, the polypeptide localized in the exosome or its functional variant forms a fusion protein with the RNA-binding polypeptide or its functional variant. In some embodiments, the polypeptide or its functional variant in the exosome is linked to the RNA-binding polypeptide or its functional variant directly or via a linker.

[0029] In some embodiments, the RNA-binding polypeptide can be selected from, but is not limited to, Ku protein, Sm7 protein, MS2 coat protein (MCP), PP7 coat protein (PCP), λN protein, Com RNA-binding protein, aptamer, or any combination, functional variant, fragment or domain thereof. In some embodiments, the RNA-binding polypeptide can be MS2 coat protein (MCP), PP7 coat protein (PCP), λN22 protein, or any combination, functional variant, fragment or domain thereof.

[0030] In some embodiments, the RNA-binding polypeptide can have an amino acid sequence as shown in SEQ ID NO:4, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence as shown in SEQ ID NO:4.

[0031] In some embodiments, the RNA-binding polypeptide can have the amino acid sequence as shown in SEQ ID NO:9, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to the amino acid sequence as shown in SEQ ID NO:9.

[0032] In some embodiments, the RNA-binding polypeptide can have an amino acid sequence as shown in SEQ ID NO: 10, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence as shown in SEQ ID NO: 10.

[0033] In some embodiments, the extracellular vesicle-localized polypeptide can be linked to the RNA-binding polypeptide via a linker.

[0034] In some embodiments, the second RNA motif may include one or more RNA sequences specifically recognized and bound by B. In some embodiments, the second RNA motif may be one or more selected from the group consisting of a telomerase Ku binding motif, a telomerase Sm7 binding motif, an MS2 phage operator stem-loop, a PP7 phage operator stem-loop, a boxB RNA stem-loop, an SfMu phage Com stem-loop, a non-natural RNA aptamer, and the like.

[0035] In some embodiments, the RNA-binding polypeptide is capable of specifically binding to the second RNA motif. For example, the RNA-binding polypeptide-RNA motif binding pair can include Ku protein-Ku binding motif, Sm7 protein-telomerase Sm7 binding motif, MS2 coat protein (MCP)-MS2 phage operator stem-loop, PCP-PP7 phage operator stem-loop, λN22 protein-boxB RNA stem-loop, Com RNA binding protein-Com stem-loop, aptamer ligand-corresponding RNA aptamer.

[0036] In some embodiments, the telomerase Ku binding motif can have a sequence as shown in 5′-UUCUUGUCGUACUUAUAGAUCGCUACGUUAUUUCAAUUUUUGAAAAUCUGAGUCCUGGGAGUGCG-3′ (SEQ ID NO: 65).

[0037] In some embodiments, the telomerase Sm7 binding motif can have a sequence as shown in 5'-AAUUUUUGGA-3' (SEQ ID NO: 66).

[0038] In some embodiments, the MS2 phage operator stem-loop can have a sequence as shown in 5'-GCGCACAUGAGGAUCACCCAUGUGC-3' (SEQ ID NO: 67).

[0039] In some embodiments, the PP7 phage operator stem-loop can have a sequence as shown in 5'-GGAGCAGACGAUAUGGCGUCGCUCC-3' (SEQ ID NO: 68).

[0040] In some embodiments, the SfMu phage Com stem-loop can have a sequence as shown in 5'-CUGAAUGCCUGCGAGCAUC-3' (SEQ ID NO: 69).

[0041] In some embodiments, the boxB RNA stem-loop can have a sequence as shown in 5'-GGGCCCUGAAGAAGGGCCC-3' (SEQ ID NO: 70).

[0042] In some embodiments, the second RNA motif may include single or multiple copies of a telomerase Ku binding motif, a telomerase Sm7 binding motif, an MS2 phage operator stem-loop, a PP7 phage operator stem-loop, an SfMu phage Com stem-loop, a non-natural RNA aptamer, etc. In some embodiments, the second RNA motif may include multiple copies of these RNA motifs.

[0043] In some embodiments, the first RNA motif may include, but is not limited to, one or more guide RNAs (sgRNAs), shRNAs, or siRNAs. The first RNA motif is complementary to one or more target sequences and can knock down or increase the expression of the one or more target sequences.

[0044] In some embodiments, the first RNA motif can be an sgRNA. In this case, the system further comprises a CRISPR-associated protein coding region. In some embodiments, the CRISPR-associated protein can be a CRISPR effector protein conventionally used in the art, which can target a specific gene (DNA) sequence under the guidance of the sgRNA. In some embodiments, the CRISPR effector protein can target activation or inhibition of the expression of a specific gene.

[0045] In some embodiments, the CRISPR effector protein can be selected from Cas9, Cas12 (e.g., Cas12a, Cas12b) or Cas13 (e.g., Cas13a1, Cas13a2, Cas13b), or a fragment thereof.

[0046] In some embodiments, the CRISPR effector protein can be Cas9, or a fragment thereof. In some embodiments, the CRISPR effector protein can have the amino acid sequence shown in SEQ ID NO: 9, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 9.

[0047] In some embodiments, the formula I may further include a CRISPR-associated protein coding region. In some embodiments, in the formula I, B is connected to the CRISPR-associated protein (Cas) coding region via a linker coding region. In some embodiments, the linker may be selected from (GmS)n, (G)n, (EAAAK)n, or (XP)n, wherein m and n are each independently selected from an integer of 1 to 5.

[0048] In some embodiments, the barcode sequence can indicate the sequence of the first RNA motif. In some embodiments, the sequence of the first RNA motif can be determined by sequencing the barcode sequence. In some embodiments, the barcode sequence can be a unique molecular identifier (UMI) sequence.

[0049] In some embodiments, the exosome targeting region of Formula I is operably linked to a first regulatory element. In some embodiments, the first regulatory element may be a type II promoter. In some embodiments, the first regulatory element may be selected from mammalian constitutive promoters, including, but not limited to, β-actin promoter (ACTB), CMV (cytomegalovirus) promoter; EF1A (elongation factor-1α) promoter; EFS promoter; CAG (cytomegalovirus enhancer and chicken β-actin promoter); CBh promoter; SFFV promoter; MSCV promoter; SV40 (simian virus derived) promoter; mPGK promoter; hPGK (phosphoglycerate kinase) promoter; UBC (ubiquitin C) promoter.

[0050] In some embodiments, in the screening region shown in Formula II, the barcode sequence (D) and the encoding nucleotide sequence (E) of the second RNA motif are transcribed in tandem. In some embodiments, the encoding nucleotide sequence (C) of the first RNA motif is operably connected to a second regulatory element, and the barcode sequence (D) and the encoding nucleotide sequence (E) of the second RNA motif are operably connected to a third regulatory element. In some embodiments, the second regulatory element and the third regulatory element can be type III promoters, such as U6 and H1 promoters. In some embodiments, the second regulatory element and the third regulatory element can be the same or different.

[0051] In some embodiments, the extracellular vesicle targeting region shown in Formula I and the screening region shown in Formula II can be in the same vector, or in different vectors.

[0052] In some embodiments, the vector can be a non-viral vector or a viral vector. In some embodiments, the viral vector can be selected from adenoviral vectors, adeno-associated viral vectors (AAV), retroviral vectors, lentiviral vectors, Newcastle disease virus (NDV) vectors, lymphocytic choriomeningitis virus (LCMV) vectors, etc.

[0053] According to another aspect of the present disclosure, an exosome is provided, comprising the fusion protein of the present disclosure. In some embodiments, the exosome may further comprise a barcode sequence of the system of the present disclosure and a nucleotide sequence encoding a second RNA motif.

[0054] According to yet another aspect of the present disclosure, an isolated nucleic acid molecule is provided, wherein the nucleic acid molecule encodes the above-mentioned fusion protein of the present disclosure.

[0055] According to another aspect of the present disclosure, an isolated nucleic acid molecule is provided, which encodes the extracellular vesicle targeting region shown in Formula I and / or the screening region shown in Formula II of the above-mentioned system of the present disclosure.

[0056] According to another aspect of the present disclosure, a host cell is provided, which includes the above-mentioned nucleic acid molecule of the present disclosure.

[0057] According to yet another aspect of the present disclosure, a screening method is provided, wherein the screening method uses the above-mentioned system of the present disclosure to screen genes that affect the production of extracellular vesicles.

[0058] In some embodiments, the screening method comprises: 1) introducing the above-described system of the present disclosure into a cell; 2) allowing the first RNA motif to hybridize with a target sequence to knock out or knock down the expression of the target sequence; and, 3) obtaining information about the first RNA motif corresponding to the barcode sequence by detecting the barcode sequence, thereby obtaining information about the target sequence that affects extracellular vesicle production. In some embodiments, the target sequence is extrachromosomal DNA and / or genomic DNA.

[0059] In some embodiments, step 3) can include sequencing the cell genome and cDNA obtained by reverse transcription of extracellular vesicle RNA to obtain the rate of change of the barcode sequence. In some embodiments, step 3) can include separately obtaining the relative abundance of DNA fragments corresponding to the first RNA motif on the cell genome and the relative abundance of the barcode sequence in extracellular vesicles.

[0060] In some embodiments, affecting extracellular vesicle production may include increasing or decreasing extracellular vesicle production.

[0061] The screening system disclosed herein can be used to screen for genes that affect extracellular vesicle secretion, such as genes that can increase or decrease extracellular vesicle secretion. In some embodiments, for genes that can decrease extracellular vesicle secretion, the expression of the gene can be knocked down or knocked out in cells to increase extracellular vesicle secretion. In other embodiments, for genes that can increase extracellular vesicle secretion, the expression of the gene can be overexpressed in cells to enhance extracellular vesicle secretion. BRIEF DESCRIPTION OF THE DRAWINGS

[0062] FIG1 schematically shows the expression plasmid of the extracellular vesicle scaffold protein.

[0063] Figure 2 shows the morphology and particle size distribution of exosomes according to one embodiment of the present disclosure. Figure 2A shows a photograph of the morphology of exosomes produced by cells detected by transmission electron microscopy; Figure 2B shows the distribution of exosome particle size detected by Nanoflow.

[0064] Figure 3 shows the protein distribution and expression results on exosomes according to one embodiment of the present disclosure. Figure 3A shows the protein distribution on exosomes; Figure 3B shows the expression of fluorescent proteins in exosomes.

[0065] Figure 4 exemplifies an expression plasmid for an exosome scaffold protein and sgRNA according to one embodiment of the present disclosure. Figure 4A is a schematic diagram of an expression plasmid for an exosome scaffold protein and an RNA-binding polypeptide; Figure 4B is a schematic diagram of an expression plasmid for an sgRNA.

[0066] Figure 5 shows the morphology and particle size distribution of exosomes according to one embodiment of the present disclosure. Figure 5A shows a photograph of the morphology of exosomes produced by cells detected by transmission electron microscopy; Figure 5B shows the distribution of exosome particle size detected by Nanoflow.

[0067] FIG6 shows the relative expression levels of UMIs in exosomes according to one embodiment of the present disclosure.

[0068] Figure 7 shows the morphology and size distribution of exosomes according to one embodiment of the present disclosure. Figures 7A to 7C show the morphology (top) and size distribution (bottom) of exosomes secreted by 293T cells transfected with MCP / MS2, PCP / PP7, and λN22 / boxB, respectively.

[0069] FIG8 shows the relative expression levels of UMIs in exosomes according to one embodiment of the present disclosure.

[0070] FIG9 shows the expression results of BASP1 according to one embodiment of the present disclosure.

[0071] Figure 10 shows the results of transfection with RAB7 or CD276 sgRNA according to one embodiment of the present disclosure. Figures 10A and 10C show the protein expression results and quantification results after transfection with RAB7 sgRNA, respectively; Figures 10B and 10D show the protein expression results and quantification results after transfection with CD276 sgRNA, respectively.

[0072] FIG11 shows the morphology and particle size distribution results of exosomes according to one embodiment of the present disclosure.

[0073] FIG12 shows the results of detecting the expression of various proteins in exosomes according to one embodiment of the present disclosure, wherein lane 2 is a cell sample of 293T cells and the other lanes are exosome samples.

[0074] FIG13 shows the results of detecting the expression of UMIs in exosomes according to one embodiment of the present disclosure. The figure shows the results after the amount of UMIs is normalized to the amount of GAPDH.

[0075] FIG14 shows the UMI change results after treatment with different sgRNAs according to one embodiment of the present disclosure. DETAILED DESCRIPTION

[0076] Under normal physiological conditions or under external stimulation, cells can secrete a type of vesicles with membrane structure, collectively called extracellular vesicles.

[0077] Extracellular vesicles are classified into various subtypes based on size, synthesis method, and biological properties. Extracellular vesicles from different cell sources can also vary greatly in function. Extracellular vesicles can be divided into the following categories based on their biosynthesis or release pathway: exosomes, which originate from the endocytic pathway, have a diameter of 30 to 200 nm and a density of approximately 1.11 to 1.19 g / mL; microparticles / microvesicles, which are released directly from the plasma membrane and have a diameter of approximately 100 to 1000 nm; apoptotic bodies (blebs), which are produced by apoptosis and have a diameter of approximately 50 nm to 2 μm; large oncosomes, which are released from tumor cells and have a diameter of approximately 1 to 10 μm; and various other extracellular vesicle subpopulations. Clinical research primarily focuses on exosomes.

[0078] Exosomes originate from the endocytic pathway. Classical exosome formation begins with the formation of secretory endosomes through the invagination of the cytoplasmic membrane. During exosome formation, cytosolic proteins, nucleic acids, and lipids are selectively encapsulated within exosomes. Exosomes inherit many specific biomolecules from their parent cells, contributing to their heterogeneity. Exosomes can mediate immune responses, antigen presentation, cell migration, cell differentiation, and tumor invasion, and their functions depend on the cell type from which they originate.

[0079] The substances carried by exosomes are related to the cells from which they originate. This heterogeneity also makes exosomes possible for the diagnosis or detection of diseases.

[0080] The therapeutic potential of exosomes as drugs or as drug delivery vehicles is being actively explored. Compared to liposomes, injected exosomes can effectively enter other cells and can deliver functional molecules with minimal immune clearance after exogenous administration in mice. In addition, the therapeutic application of exosomes is promising because they have been shown to be well tolerated. Exosomes derived from mesenchymal cells (MSCs) and epithelial cells do not induce toxicity when repeatedly injected in mice. MSC-derived exosomes have been proposed as a treatment in themselves, and the use of MSC-derived exosomes to treat patients with graft-versus-host disease has shown that repeated injections are well tolerated, without substantial side effects, and without causing patient reactions.

[0081] Exosomes may also enable the development of receptor-mediated tissue targeting based on their surface ligand presentation. Ligand enrichment on engineered exosomes can also be used to induce or inhibit signaling events in recipient cells or to target exosomes to specific cell types.

[0082] The screening system disclosed herein can screen genes that affect the generation of extracellular vesicles or exosomes (e.g., biogenesis), providing a possibility for improving the generation of exosomes.

[0083] In some embodiments, the present disclosure utilizes the CRISPR / Cas system. In specific embodiments, the present disclosure utilizes the CRISPR / Cas9 system. Cas9 is a type II CRISPR (clustered regularly interspaced short palindromic repeats) system from microorganisms, which has been shown to cleave DNA when paired with a single guide RNA (gRNA). Cas9 primarily cleaves genomic sites where the gRNA sequence is followed by a PAM sequence (-NGG).

[0084] In some embodiments, the present disclosure relates to using the CRISPR / Cas system, where the Cas protein cooperates with sgRNA to achieve a knockdown or knockout effect on a targeted gene. Each barcode sequence is specific to an sgRNA and corresponds to a targeted gene. The barcode sequence is brought into the exosome together with the second RNA motif by the fusion protein encoded by the exosome targeting region shown in Formula I. The specific sgRNA sequence to which the barcode sequence is connected is determined by sequencing the barcode sequence in the exosome, thereby screening for genes related to the amount of exosome secretion, etc.

[0085] In some embodiments, the CRISPR / Cas system nuclease requires sgRNA to cut genomic DNA. These sgRNAs are composed of the following: (1) a spacer of 19 to 21 nucleotides of a variable sequence (guide sequence), which enables the CRISPR / Cas system nuclease to target genomic sites in a sequence-specific manner, and (2) an invariant hairpin sequence, which is constant between guide RNAs and allows the guide RNA to bind to the CRISPR / Cas system nuclease. In the presence of CRISPR / Cas nuclease, the guide RNA triggers a CRISPR / Cas-based genome cutting event in the cell. It should be understood that any hairpin sequence can be used as long as it can be recognized and bound by the CRISPR / Cas nuclease.

[0086] In some embodiments, the system of the present disclosure can also include the coding sequence of a reporter factor. In some embodiments, the reporter factor is used to identify the cell potentially transfected and is used to assess the function of the regulatory sequence. Generally speaking, the reporter factor is not an endogenous or original gene for the host cell, and the protein encoded by it can be easily measured. In some embodiments, the reporter factor is known in the art, and includes but is not limited to green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), glutathione S transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, beta-glucuronidase, luciferase, HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), blue fluorescent protein (BFP), cell surface markers, resistance genes (such as neo antibiotics), etc.

[0087] To make the objectives, technical solutions, and advantages of the present invention more clearly understood, the present invention will be further described in detail below with reference to the following examples. The specific embodiments described herein are intended only to illustrate the present invention and are not intended to limit the present invention in any way. In addition, in the following description, descriptions of known structures and technologies are omitted to avoid unnecessary confusion about the concepts of the present disclosure. Such structures and technologies are also described in many publications.

[0088] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly used in the field to which the present invention belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa.

[0089] Unless the context clearly dictates otherwise, as used herein, the expressions "a" and "an" include plural references. For example, reference to "a cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art, and so forth.

[0090] As used herein, the term "about" refers to a range of ±20% of the value that follows. In some embodiments, the term "about" refers to a range of ±10% of the value that follows. In some embodiments, the term "about" refers to a range of ±5% of the value that follows.

[0091] The terms "extracellular vesicle", "exovesicle" or "EV" as used herein refer to cell-derived vesicles comprising a membrane that encapsulates an internal space. Extracellular vesicles include all membrane-bound vesicles (e.g., exosomes, microvesicles, apoptotic bodies, tumor vesicles, nanovesicles, etc.) whose diameters are smaller than the diameter of the cells from which they are derived. In some aspects, the diameter of the extracellular vesicle is in the range of 20 nm to 1000 nm and may be contained within the internal space (i.e., cavity), displayed on the outer surface of the extracellular vesicle and / or across the membrane. In some aspects, the payload may include nucleic acids, proteins, carbohydrates, lipids, small molecules and / or combinations thereof. In some aspects, the extracellular medium comprises a scaffold portion. By way of example and not limitation, extracellular vesicles include apoptotic bodies, cell fragments, cell-derived vesicles obtained by direct or indirect manipulation (e.g., by continuous extrusion or treatment with an alkaline solution), vesicles of vesicled organelles and vesicles produced by living cells (e.g., by direct plasma membrane budding or late endosome fusion with the plasma membrane). The extracellular vesicles can be derived from living or dead organisms, explanted tissues or organs, prokaryotic or eukaryotic cells and / or cultured cells. In some aspects, the extracellular vesicles are produced by cells expressing one or more transgene products.

[0092] The term "exosome" as used herein refers to an extracellular vesicle with a diameter between 30 and 200 nm (e.g., between 40 and 200 nm). Exosomes include a membrane that encapsulates an internal space, and in some aspects, can be produced by cells by direct plasma membrane budding or by fusion of late endosomes or multivesicular bodies with the plasma membrane. In certain aspects, exosomes include a scaffold portion. As described below, exosomes can be derived from producer cells and isolated from producer cells based on their size, density, biochemical parameters, or a combination thereof. In some aspects, the EVs (e.g., exosomes) of the present disclosure are produced by cells expressing one or more transgenic products. In some embodiments, the diameter of the exosomes can be 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 150 nm, 160 nm, 170 nm, 180 nm, 190 nm, 200 nm.

[0093] The term "membrane-associated protein" or "membrane-associated polypeptide" as used herein refers to a protein or peptide associated with the membrane of an extracellular vesicle, and may include proteins that are integrated into the membrane of an extracellular vesicle, protruding outside the extracellular vesicle, or inside the extracellular vesicle.

[0094] As used herein, the term "replacement" or "substitution" of an amino acid may refer to a conservative amino acid substitution, wherein an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues with similar side chains have been defined in the art and include basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, if an amino acid in a polypeptide is replaced with another amino acid from the same side chain family, the substitution is considered conservative. In another aspect, a string of amino acids can be conservatively substituted with a structurally similar string that differs in the order and / or composition of side chain family members.

[0095] "Percent sequence identity" or "percent identity" between two polynucleotide or polypeptide sequences refers to the number of identical matched positions shared by the sequences over the comparison window, taking into account additions or deletions (i.e., gaps) that must be introduced for optimal alignment of the two sequences. A matched position is any position where the same nucleotide or amino acid is present in both the target sequence and the reference sequence. Since a gap is not a nucleotide or amino acid, gaps present in the target sequence are not counted. Similarly, since target sequence nucleotides or amino acids are counted and nucleotides or amino acids from the reference sequence are not counted, gaps present in the reference sequence are not counted.

[0096] Percentage sequence identity can be calculated by the following process: determine that the number of positions where identical amino acid residues or nucleic acid bases occur in both sequences, to obtain the number of matched positions, the number of matched positions divided by the total number of positions in the comparison window, and multiply the result by 100, to obtain percent sequence identity. The determination of percent sequence identity between the comparison of a sequence and two sequences can be accomplished using software that is easy to use online and download. Suitable software programs can be obtained from various sources for the comparison of protein and nucleotide sequences. A suitable program for determining percent sequence identity is bl2seq, which is a part for the BLAST suite of programs that can be obtained from the BLAST website (blast.ncbi.nlm.nih.gov) of the National Center for Biotechnology Information of the U.S. Government. Bl2seq uses BLASTN or BLASTP algorithms to compare between two sequences. BLASTN is used for comparing nucleic acid sequences, and BLASTP is used for comparing amino acid sequences. Other suitable programs are, for example, Needle, Stretcher, Water or Matcher, part of the EMBOSS suite of bioinformatics programs and also available from the European Bioinformatics Institute (EBI) at www.ebi.ac.uk / Tools / psa.

[0097] The term "host cell" as used herein refers to a cell used to produce extracellular vesicles. Host cells can be cells cultured in vitro or in vivo. Host cells include, but are not limited to, cells known to be able to effectively produce extracellular vesicles, such as HEK293 cells, Chinese hamster ovary (CHO) cells, mesenchymal stem cells (MSCs), fibroblasts, neuronal precursor cells (e.g., neuronal precursor cells), amniotic fluid cells (e.g. amniocytes), adipose-derived mesenchymal stem cells, and RPTEC / TERT1 cells.

[0098] As used herein, the terms "individual," "subject," "host," and "patient" are used interchangeably herein and refer to any mammalian subject, particularly a human, in need of diagnosis, treatment, or therapy. The compositions and methods described herein are suitable for human therapy and veterinary applications. In some aspects, the subject is a mammal, and in other aspects, the subject is a human. As used herein, "mammalian subject" includes all mammals, including but not limited to humans, domestic animals (e.g., dogs, cats, etc.), farm animals (e.g., cattle, sheep, pigs, horses, etc.), and laboratory animals (e.g., monkeys, rats, mice, rabbits, guinea pigs, etc.).

[0099] The term "connector" as used herein refers to a (peptide) linker of natural and / or synthetic origin, consisting of linear amino acids. The domains in the bispecific fusion polypeptide of the present invention can be connected by a connector, wherein each connector is fused to at least two polypeptides or domains and / or connected in other ways (e.g., via a peptide bond). In some embodiments, the amino acid sequences of all connectors present in the bispecific fusion polypeptide of the present invention are identical. In other embodiments, the amino acid sequences of at least two connectors present in the bispecific fusion polypeptide of the present invention are different. The connector should have a length suitable for connecting two or more monomer domains in this way, and the connector can ensure that the different domains it connects are correctly folded and appropriately presented, thereby exerting the function of its biological activity. In different embodiments, the connector has a flexible conformation. Suitable flexible connectors include, for example, having glycine, glutamine and / or serine residues. In some embodiments, the connector can be selected from (G, N ... n S) m 、(G) n 、(EAAAK) n or (XP) n , wherein n and m are each independently selected from an integer of 0 to 5. For example, n is selected from 0, 1, 2, 3, 4 or 5, and m is selected from 1, 2, 3, 4 or 5. In some embodiments, the linker may further include, for example, KESGSVSSEQLAQFRSLD (SEQ ID NO: 71), EGKSSGSGSESKST (SEQ ID NO: 72), GGGGGGGG (SEQ ID NO: 73), GSAGSAAGSGEF (SEQ ID NO: 74), etc.

[0100] The term "barcode sequence" as used herein refers to a barcode chain portion comprising a nucleic acid sequence representing space, sequencing information and / or encoding data. The barcode sequence can be predetermined by a barcode library. The barcode sequence may be a sequence comprising DNA, RNA, synthetic nucleobases, or any combination thereof. In some embodiments of the present disclosure, the barcode sequence may be unique and correspond to the sgRNA to which it is connected. During sequencing, the barcode sequence can be used to distinguish samples or to distinguish a nucleotide sequence of different sequences to be tested in a sample. As will be appreciated by those skilled in the art, the length of the barcode sequence can be determined as needed and the library capacity. Those skilled in the art will also appreciate that barcode sequences can also be used to distinguish different sequencing samples in commonly used second-generation sequencing platforms (such as the Illumina sequencing platform). In some embodiments, the barcode sequence can be approximately 6 to 30 bp in length, for example, 6 bp, 7 bp, 8 bp, 9 bp, 10 bp, 11 bp, 12 bp, 13 bp, 14 bp, 15 bp, 16 bp, 17 bp, 18 bp, 19 bp, 20 bp, 21 bp, 22 bp, 23 bp, 24 bp, 25 bp, 26 bp, 27 bp, 28 bp, 29 bp, or 30 bp. In some embodiments, the barcode sequence can include a unique molecular identifier (UMI).

[0101] The term "operably connected" as used herein refers to the connection of at least the first element and the second element so that the constituent elements are in a relationship that allows them to work in their intended manner. For example, if a regulatory sequence (such as a promoter sequence) and a coding sequence are connected in a manner that allows the expression of the coding sequence to be controlled by the regulatory sequence, then the nucleic acid regulatory sequence is "operably connected" to the nucleic acid coding sequence. In some embodiments, the regulatory sequence "operably connected" is covalently bound directly or indirectly to the coding sequence (for example, in a single nucleic acid molecule). In some embodiments, the regulatory sequence controls the expression of the coding sequence in a trans manner, and it is not a requirement for operable connection to include the regulatory sequence in the nucleic acid identical to the coding sequence.

[0102] A recombinant expression vector may comprise a nucleic acid according to the present invention in a form suitable for expressing the nucleic acid in a host cell, which means that the recombinant expression vector includes one or more regulatory elements, which may be selected based on the host cell to be used for expression, and which are operably linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" means that the nucleotide sequence of interest is linked to the regulatory elements in a manner that allows expression of the nucleotide sequence (e.g., in an in vitro transcription / translation system or in a host cell when the vector is introduced into the host cell).

[0103] Type III promoters (U6, H1) mainly express non-coding short sequence RNA, such as sgRNA, shRNA, miRNA, etc.

[0104] Type II promoters can be divided into three categories based on their usage characteristics: constitutive promoters (universal promoters), tissue-specific promoters, and inducible promoters. Specific promoters can only be expressed in specific cells and are therefore suitable for animal experiments. Inducible promoters require the addition of specific drugs to stimulate or inhibit their activity, such as tetracycline-induced TRE / TRE3G expression. Constitutive promoters (universal promoters) are the most commonly used in expression systems. These promoters can maintain a certain level of expression activity in most cells, although different promoters can also have different expression levels.

[0105] The following examples and accompanying drawings are provided to facilitate understanding of the present invention. However, it should be understood that these examples and accompanying drawings are intended to illustrate the present invention only and are not intended to limit the present invention in any way. The actual scope of protection of the present invention is set forth in the claims. It should be understood that any modifications and variations may be made without departing from the spirit of the present invention.

[0106] Example

[0107] Example 1: Testing the effect of different polypeptides localized in extracellular vesicles.

[0108] The nucleic acid sequences encoding the exosome scaffold proteins BASP1, CD63, and SDCBP were respectively constructed into the pcDNA3.1(+) plasmid (Universal Biological) vector to obtain the plasmids pcDNA3.1-BASP1-EGFP-Nanoluc, pcDNA3.1-CD63-EGFP-Nanoluc, and pcDNA3.1-SDCBP-Nanoluc. For ease of detection, EGFP-Nanoluc was attached to the C-termini of BASP1, CD63, and SDCBP. Briefly, the nucleic acid sequences encoding BASP1, CD63, SDCBP, EGFP, and Nanoluc were synthesized according to the amino acid sequences given in Table 1 below and commonly used in the art, and were respectively inserted into the multiple cloning site of the pcDNA3.1(+) vector to obtain the target plasmids. Figure 1 exemplifies the constructed plasmids.

[0109] Table 1

[0110] 20,000 pieces / cm 2293T cells were plated at a density of 100 μg / mL in T225 cell culture flasks and cultured overnight in DMEM (Gibco) supplemented with 10% fetal bovine serum. 293T cells were transfected with the plasmids pcDNA3.1-BASP1-EGFP-Nanoluc, pcDNA3.1-CD63-EGFP-Nanoluc, and pcDNA3.1-SDCBP-EGFP-Nanoluc, respectively. Cells transfected with the pcDNA3.1 plasmid served as a control. After 72 hours, the cell culture supernatant was collected and exosomes were isolated and purified.

[0111] Transmission electron microscopy and Nanoflow were used to detect the morphology and particle size distribution of exosomes in different groups. The results are shown in Figure 2. The transmission electron microscopy images showed that the exosomes produced by cells in each group had a typical saucer-shaped morphology (Figure 2A). The Nanoflow detection results showed that the exosome particle size was mainly distributed between 30 and 200 nm (Figure 2B).

[0112] In addition, the proportion of exosomes containing green fluorescence in each group was detected by the FITC channel of Nanoflow, and the distribution ratio of the BASP1 / CD63 / SDCBP protein fused with it in the exosomes was known. Nano-glo was used to detect the expression level of Nanoluc in the exosomes of each group (the stronger the luminescent signal, the higher the expression level of Nanoluc), and the content of the fused BASP1 / CD63 / SDCBP protein in the exosomes was known. The results are shown in Figures 3A and 3B. As can be seen from Figure 3A, BASP1 is more widely distributed in exosomes than CD63 and SDCBP proteins. As can be seen from Figure 3B, the content of BASP1 in exosomes is higher than that of CD63 and SDCBP proteins.

[0113] Example 2: Comparison of the loading effects of different peptides localized in extracellular vesicles on UMI molecules.

[0114] As shown in Figure 4A, Lenti-CMV-BASP1-MCP-EF-1α-Cas9, Lenti-CMV-CD63-MCP-EF-1α-Cas9, and Lenti-CMV-SDCBP-MCP-EF-1α-Cas9 plasmids (with a FLAG tag between BASP1 and MCP) were constructed. Briefly, nucleic acid sequences encoding BASP1, CD63, SDCBP, MCP, and Cas9 were synthesized according to the amino acid sequences given in Tables 1 and 2 and commonly used in the art and inserted between the cPPT / CTS and EF-1α core promoter elements of the LentiCas9-Blast plasmid (Addgene, #52962).

[0115] The Lenti-mU6-sgRNA-hU6-NC-MS2 plasmid was constructed as shown in Figure 4B. Briefly, the mU6-sgRNA-hU6-NC-MS2 and P2A sequences were synthesized according to the sequences given in Table 2, and the U6-EF-1α sequence in the LentiGuide-Puro (Addgene, #52963) plasmid was replaced to obtain the target plasmid.

[0116] Table 2.

[0117] At 20,000 cells / cm 2 293T cells were plated at a density of 100 μg / mL in a T225 cell culture flask and cultured overnight in DMEM (Gibco) supplemented with 10% fetal bovine serum. Plasmids 1 and 2 were co-transfected into the cells according to Table 3. LentiCas9-Blast plasmid was transfected as a control. After 72 hours, the cell culture supernatant was collected and exosomes were isolated and purified.

[0118] Table 3.

[0119] Transmission electron microscopy and Nanoflow were used to examine the morphology ( Figure 5A ) and size distribution ( Figure 5B ) of exosomes from different groups.

[0120] In addition, 200 μL of exosomes from each group were extracted for total RNA using the miRNeasy Serum / Plasma Kit (50) (Qiagen) according to the manufacturer's instructions. Equal amounts of RNA were then used for RT-qPCR analysis using primers F: ACACTCTTTCCCTACACGACGCT (SEQ ID NO: 75) and R: GACTGGAGTTCAGACGTGTGCT (SEQ ID NO: 76) to analyze the loading of UMI molecules in the exosomes of each group. The results are shown in Figure 6.

[0121] Example 3: Comparison of the effect of different RNA-binding proteins / RNA on the loading of UMIs into exosomes

[0122] In the Lenti-CMV-BASP1-MCP-EF-1α-Cas9 plasmid constructed in Example 2, MCP was replaced with PCP or λN22 to generate the Lenti-BASP1-PCP and Lenti-BASP1-λN22 plasmids, respectively. Correspondingly, MS2 in the sgRNA-NC-MS2 plasmid was replaced with PP7 or boxB. Table 4 below shows the amino acid sequences of PCP and λN22, as well as the nucleic acid sequences encoding PP7 and boxB.

[0123] Table 4.

[0124] 20,000 pieces / cm 2 293T cells were plated at a density of 1:1 in a T225 cell culture flask and cultured overnight in DMEM medium (Gibco) containing 10% fetal bovine serum. Plasmid 1 and plasmid 2 were co-transfected into the cells according to Table 5 below.

[0125] The cells were transfected with the corresponding plasmids according to Table 5 below. After 72 hours, the cell culture supernatant was collected and the exosomes were isolated and purified.

[0126] Table 5.

[0127] Transmission electron microscopy and Nanoflow were used to detect the morphology ( Figures 7A to 7C , upper panels) and particle size distribution ( Figures 7A to 7C , lower panels) of exosomes in different groups.

[0128] In addition, 200 μL of exosomes from each group were extracted for total RNA according to the instructions of the miRNeasy Serum / Plasma Kit (50) (Qiagen). Equal amounts of RNA were used for RT-qPCR using primers F: ACACTCTTTCCCTACACGACGCT (SEQ ID NO: 75) and R: GACTGGAGTTCAGACGTGTGCT (SEQ ID NO: 76) to analyze the loading of UMI molecules in the exosomes of each group. The results are shown in Figure 8. The results show that when using different RNAs and their corresponding RNA-binding peptides, MCP / MS2 has a significantly better loading effect on UMI molecules than PCP / PP7 and λN22 / boxB.

[0129] Example 4: Construction of BASP1-MCP monoclonal cells

[0130] In this example, the Lenti-CMV-BASP1-MCP-EF-1α-Cas9 plasmid constructed in Example 2 was used.

[0131] To validate the disclosed system, corresponding sgRNAs and UMI sequences were designed based on the RAB7 and CD276 gene sequences (as shown in Table 6 below). As shown in Figure 4B, sgRNA-UMI-MS2 plasmids were constructed. The resulting plasmids were named sgRNA-UMI-RAB7-MS2 and sgRNA-UMI-CD276-MS2, respectively. The sgRNA-UMI-NC-MS2 plasmid served as a control plasmid.

[0132] Table 6.

[0133] HEK293 T cells were plated in 6-well plates at 5 × 10 5 HEK293 T cells were cultured overnight at 37°C. The pLVX-BASP1-MCP-Cas9 lentivirus was used to infect HEK293 T cells. Wells infected with the sgRNA-UMI-NC-MS2 plasmid served as controls. After 24 hours, the culture medium was replaced with complete DMEM supplemented with 10% fetal bovine serum (FBS) containing blasticidin (BSD) (final BSD concentration: 20 μg / mL). The cells were cultured every 3 days until all cells in the control wells were dead.

[0134] The cells in the experimental group were trypsinized, diluted, and plated into 96-well plates. 300 μL of complete DMEM medium containing BSD and 10% fetal bovine serum was added to each well, resulting in a pore density of approximately 70%. The plates were cultured in a 37°C incubator. The cells in the 96-well plates were monitored every two days. When cells in wells containing monoclonal clones proliferated sufficiently, they were trypsinized and plated into 24-well plates for further culture. The cell culture system was gradually expanded to obtain BASP1-MCP monoclonal cell lines, BASP-MCP-BSD-293T-1 and BASP-MCP-BSD-293T-2.

[0135] Western blotting was performed using an anti-flag primary antibody (Abcam, ab125243) to detect BASP-1 (flag-tagged) expression in cell lines BASP-MCP-BSD-293T-1 and BASP-MCP-BSD-293T-2, as well as untransfected control 293T-1 and 293T-2 cells. Representative results are shown in Figure 9. The BASP-1-MCP monoclonal cell line with high expression (BASP-MCP-BSD-293T-2, or simply 293T-2) was selected for subsequent experiments.

[0136] Example 5. Infection of BASP1-MCP monoclonal cells using sgRNA-UMI-MS2 expression vector

[0137] The BASP1-MCP monoclonal cells (293T-2) screened in Example 4 were plated into 6-well plates, and 5×10 5Cells were cultured overnight at 37°C. BASP1-MCP monoclonal cells were infected with either sgRNA-UMI-RAB7-MS2 or sgRNA-UMI-CD276-MS2 lentivirus. The control lentivirus to cell ratio was 0.3-0.5:1. Cells infected with sgRNA-UMI-NC-MS2 lentivirus served as controls. After 24 hours, cells were replaced with DMEM complete medium supplemented with Puro and 10% fetal bovine serum (Puro final concentration 10 μg / mL). Cell culture medium was changed every 3 days until all cells in the control sample were dead.

[0138] Western blotting was used to detect the expression of RAB7, CD276, BASP-1 (with a flag tag), and Cas9 proteins in cells using anti-RAB7 (Abcam, ab137029), anti-CD276 (Abcam, ab134161), anti-flag (Abcam, ab125243), and anti-Cas9 (Abcam, ab189380) primary antibodies. The results are shown in Figures 10A to 10D. As can be seen from Figures 10A to 10D, infection with sgRNA-UMI-RAB7-MS2 and sgRNA-UMI-CD276-MS2 can significantly reduce the expression of the target genes RAB7 and CD276.

[0139] Cells infected with different lentiviruses were inoculated into T225 cell culture flasks at a density of 20,000 cells / cm 2 After 72 hours, the cell culture supernatant was collected and exosomes were isolated and purified. Transmission electron microscopy and Nanoflow cytometry were used to examine the morphology and size distribution of exosomes from different groups. The results are shown in Figure 11.

[0140] The first row of Figure 11 shows that the morphology of exosomes produced by different cell groups is cup-shaped, which is a typical exosome structure. The second row shows that the particle size distribution of exosomes produced by different cell groups is 30-200 nm.

[0141] In addition, the protein expression on the isolated exosomes was detected. Briefly, the western blot method was used to detect the expression of CD81, TSG101, GM130, and Calexin proteins in exosomes using anti-CD81 (Abcam, ab109201), anti-TSG101 (Abcam, ab125011), anti-GM130 (Abcam, ab52649), and anti-Calexin (Abcam, ab112995) primary antibodies. The results are shown in Figure 12. Figure 12 shows that the two exosome surface markers CD81 and TSG101 can be detected in exosomes, while the exosome negative proteins GM130 and Calexin cannot be detected, which is in line with expectations. In 293T cells, GM130 and Calexin proteins can be detected, while CD81 and TSG101 are almost not expressed.

[0142] In addition, the relative content of gene-specific UMI in exosomes was detected. Briefly, total RNA of exosomes was extracted using Qiagen miRNeasy Serum / Plasma Kit (Qiagen 217184), and reverse transcription was performed using All-in-One First-Strand Synthesis MasterMix (with dsDNase) (Yugong Life, EG15133S) reagent according to the reagent instructions (20 μL system). 4 μL of reverse transcription product was diluted 10 times, and 2 μL was added to 20 μL of qPCR system, and TB was used. Premix Ex Taq TM II (Tli RNaseH Plus) (TaKaRa RR820B) reagent was used, and qPCR was performed according to the instructions to detect the content of UMI in exosomes.

[0143] qPCR primers are as follows

[0144] UMI-F: 5'-TAACAACTCCGCTCCAAGGC-3' (SEQ ID NO: 17);

[0145] UMI-R: 5'-GGTGATCCTCATGTTTCGATGAAG-3' (SEQ ID NO: 18);

[0146] GAPDH-F: 5'-GGAGCGAGATCCCTCCAAAAT-3' (SEQ ID NO: 19);

[0147] GAPDH-R: 5'-GGCTGTTGTCATACTTCTCATGG-3' (SEQ ID NO: 20).

[0148] FIG13 shows the results of qPCR detection, showing the relative content of gene-specific UMI carried in exosomes, indicating that the exosome scaffold protein fused with MCP can help gene-specific UMI enter exosomes.

[0149] Example 6. Results of small-scale screening using the screening system of the present disclosure

[0150] This example used the disclosed system for small-scale screening and validation. Using sequences known to affect exosome production, we synthesized the sequences shown in Table 7 below to construct a small-scale validation screening library, sgRNA-UMI-MS2.

[0151] Table 7

[0152] Here are the steps:

[0153] (1) BASP1-MCP-Cas9 monoclonal cells were seeded into T225 flasks at 20,000 cells / cm 2 , 45mL / bottle of DMEM complete medium, culture overnight.

[0154] (2) Aspirate the culture medium in the T225 flask, mix it with sgRNA-UMI-MS2 lentivirus at 0.3 MOI, and then add the culture medium back into the T225 flask. The virus infection depth is 50,000×; the cells are cultured in a CO2 incubator.

[0155] (3) After 24 hours, replace the cells with fresh complete culture medium and culture the cells in a CO2 incubator.

[0156] (4) After 72 h, the cells were digested and 1×10 6 5.5×10 6 The cells were quickly frozen in liquid nitrogen for NGS sequencing, and the remaining cells were plated in T225 flasks at 20,000 cells / cm 2 , add DMEM complete medium and puro to a final concentration of 1ug / mL.

[0157] (5) Continue resistance screening, changing the medium every 2 days. If the cell confluency reaches 80%, subculture immediately until all control cells die.

[0158] (6) 1×10 cells were collected at each passage 6The FITC positive rate was detected by flow cytometry. If the positive rate reached 99% or above, the screening was completed. 6 The cells were quickly frozen in liquid nitrogen and used to extract genomic DNA for NGS sequencing.

[0159] (7) Take 8.75×10 8 Cells were cultured in suspension at an initial density of 1×10 6 cells / mL, use Opti-MEM serum-free medium, and add puro to a final concentration of 1ug / mL.

[0160] (8) After 72 h, the cell culture supernatant was collected and centrifuged at 300 g for 5 min; at 2000 g for 15 min; and 5.5 × 10 6 The cells were quickly frozen in liquid nitrogen and used to extract genomic DNA for NGS sequencing.

[0161] (9) Filter the cell culture supernatant using a 0.45 μm membrane; then ultrafiltration and concentration of the cell culture supernatant to separate and purify exosomes;

[0162] (10) Exosome quality control testing.

[0163] (11) Exosome total RNA (at least 20 ng) was extracted using the Qiagen miRNeasy Serum / Plasma Kit (Qiagen 217184) and reverse transcribed.

[0164] (12) Perform high-throughput sequencing of cell genomic DNA and exosome cDNA.

[0165] (13) Analysis of sequencing results.

[0166] The results are shown in Figure 14. The bar graph values ​​represent the rate of change of UMI relative to their corresponding sgRNAs ((relative abundance of exosome UMI / relative abundance of genomic sgRNA - 1) * 100%), where relative abundance of exosome UMI = abundance of a specific exosome UMI / sum of abundance of all exosome UMIs, and relative abundance of genomic sgRNA = abundance of a specific genomic sgRNA / sum of abundance of all genomic sgRNAs. The threshold is ±10%. NC-1, NC-2, and NC-3 are negative controls, whose corresponding sgRNAs do not knock out genes in cells under the action of Cas9. If the rate of change of UMI relative to its corresponding sgRNA is less than -10%, the corresponding gene is considered to promote exosome secretion; if the rate of change of UMI relative to its corresponding sgRNA is greater than 10%, the corresponding gene is considered to inhibit exosome secretion. The results of RAB7A, ALIX, RAB27B, SDCBP, TSG101, Hrs, RAB35, Vps25, ATG5, SMPD3, and STAM1 were consistent with those of existing studies.

[0167] The technical solution of the present invention is not limited to the above-mentioned specific embodiments. Any technical variations made according to the technical solution of the present invention fall within the protection scope of the present invention.

Claims

1. A fusion protein, characterized in that The fusion protein comprises: A polypeptide localized in extracellular vesicles or a functional variant thereof; and RNA binding polypeptide or a functional variant thereof.

2. The fusion protein according to claim 1, characterized in that The polypeptide localized in the exosome is a transmembrane or membrane-associated polypeptide, or a polypeptide localized inside the exosome. Preferably, the polypeptide localized in the extracellular vesicle is selected from IGSF8, CD9, CD63, CD81, PTGFRN, BASP1, BSG, MARCKS, MARCKSL1, ALIX or SDCBP, more preferably selected from BASP1, CD63 or SDCBP, or any combination, functional variant, fragment or domain thereof, and / or The RNA binding polypeptide is selected from Ku protein, Sm7 protein, MS2 coat protein, PP7 coat protein, Com RNA binding protein, λN protein or aptamer ligand, more preferably selected from MS2 coat protein, PP7 coat protein, λN22 protein, or any combination, functional variant, fragment or domain thereof.

3. A screening system, characterized in that: The screening system comprises: The exosome targeting region shown in Formula I, wherein A is a polypeptide localized in an exosome or a functional variant thereof, or a nucleotide sequence encoding the polypeptide, and B is an RNA-binding polypeptide or a functional variant thereof, or a nucleotide sequence encoding the polypeptide, AB (Formula I); and The screening region shown in formula II, wherein C is a nucleotide sequence encoding a first RNA motif, D is a barcode sequence, and E is a nucleotide sequence encoding a second RNA motif, wherein the first RNA motif is complementary to the target sequence, and the second RNA motif is an RNA sequence specifically recognized and bound by B, CDE (Formula II).

4. The system according to claim 3, characterized in that The extracellular vesicles include one or more of exosomes, microvesicles, apoptotic bodies, tumor vesicles and nanovesicles.

5. The system according to claim 3, characterized in that The polypeptide localized in the exosome is a transmembrane or membrane-associated polypeptide, or a polypeptide localized inside the exosome. Preferably, the polypeptide localized in the extracellular vesicle is selected from IGSF8, CD9, CD63, CD81, PTGFRN, BASP1, BSG, MARCKS, MARCKSL1, ALIX or SDCBP, more preferably selected from BASP1, CD63 or SDCBP, or any combination, functional variant, fragment or domain thereof, and / or The RNA binding polypeptide is selected from Ku protein, Sm7 protein, MS2 coat protein, λN protein, PP7 coat protein, Com RNA binding protein or aptamer ligand, more preferably selected from MS2 coat protein, PP7 coat protein, λN22 protein, or any combination, functional variant, fragment or domain thereof, and / or The second RNA motif is selected from one or more of a telomerase Ku binding motif, a telomerase Sm7 binding motif, an MS2 phage operator stem-loop, a PP7 phage operator stem-loop, a SfMu phage Com stem-loop, a boxB RNA stem-loop, and a non-natural RNA aptamer, and more preferably selected from an MS2 phage operator stem-loop, a PP7 phage operator stem-loop, or a boxB RNA stem-loop, and / or The first RNA motif is selected from one or more guide RNA (sgRNA), shRNA or siRNA.

6. The system according to claim 3, characterized in that The first RNA motif is one or more sgRNAs, and preferably the formula I further includes a CRISPR effector protein coding region, preferably selected from Cas9, Cas12 or Cas13, or a fragment thereof.

7. The system according to claim 3, characterized in that The exosome targeting region shown in Formula I is operably connected to a first regulatory element. Preferably, the first regulatory element is a type II promoter, more preferably a mammalian constitutive promoter.

8. The system according to claim 3, characterized in that The barcode sequence and the encoding nucleotide sequence of the second RNA motif are transcribed in tandem, Preferably, the encoding nucleotide sequence of the first RNA motif is operably linked to a second regulatory element, and the barcode sequence and the encoding nucleotide sequence of the second RNA motif are operably linked to a third regulatory element, More preferably, the second regulatory element and the third regulatory element are type III promoters, such as each independently a U6 or H1 promoter.

9. The system according to claim 3, characterized in that The exosome targeting region shown in Formula I and the screening region shown in Formula II are in the same vector, or are in different vectors respectively. Preferably, the vector is a viral vector, more preferably selected from an adenoviral vector, an adeno-associated viral vector (AAV), a retroviral vector, a lentiviral vector, a Newcastle disease virus (NDV) vector or a lymphocytic choriomeningitis virus (LCMV) vector.

10. An extracellular vesicle, characterized in that The exosomes include: The fusion protein according to claim 1 or 2, and / or The barcode sequence of the system according to claims 3 to 9 and the encoding nucleotide sequence of the second RNA motif.

11. An isolated nucleic acid molecule, characterized in that The nucleic acid molecule encodes the fusion protein according to claim 1 or 2, or the system according to claims 3 to 9.

12. A host cell, characterized in that The host cell comprises the nucleic acid molecule of claim 11.

13. A screening method, characterized in that: The screening method uses the system of claims 3 to 9 to screen for genes that affect the production of extracellular vesicles; Preferably, the screening method comprises: (1) introducing the system into cells; (2) allowing the first RNA motif to hybridize to a target sequence to knock out or knock down the expression of the target sequence; and, (3) By detecting the barcode sequence, information of the first RNA motif corresponding to the barcode sequence is obtained, thereby obtaining target sequence information that affects the generation of extracellular vesicles.

Citation Information

Patent Citations

  • Exosomes comprising RNA therapeutics

    CN111629760A

  • Targeted exosomes for delivery of RNA

    CN113527519A

  • Fusion RNA and exosome delivery system thereof

    CN114591989A

  • Exosomes Comprising RNA Therapeutics

    US20210369865A1

  • Library of barcoded extracellular vesicles

    US20220411785A1

Cited By

  • Universal engineering exosome construction method based on bidirectional load module

    CN120519522A